Organization and Description of the Business	9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of the Business	1. Organization and Description of the Business Description of the Business Tenaya Therapeutics, Inc. (Company) was incorporated in the state of Delaware in August 2016 and is headquartered in South San Francisco, California. The Company is a clinical-stage biotechnology company focused on discovering, developing and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing product candidates from three distinct but interrelated product platforms: gene therapy, cellular regeneration and precision medicine. Liquidity The Company has incurred net losses since inception and expects such losses to continue in the future as it conducts research and development activities. As of September 30, 2022, the Company had an accumulated deficit of $245.7 million. The Company incurred a net loss of $90.1 million and $46.6 million during the nine months ended September 30, 2022 and 2021, respectively. The Company had $149.5 million of cash, cash equivalents and investments in marketable securities as of September 30, 2022. Management recognizes the need to raise additional capital to fully implement its business plan. The Company may seek to raise capital through equity financings, debt financings, license agreements, collaborative agreements or other sources of financing. Management believes that its existing cash, cash equivalents and investments in marketable securities as of September 30, 2022 will be sufficient to fund the Company’s operations for at least the next twelve months following the date these condensed financial statements are filed with the Securities and Exchange Commission (SEC). In August 2022, the Company entered into a sales agreement with a sales agent to establish an at-the-market (ATM) offering program under the Securities Act. Pursuant to the sales agreement, the Company is permitted to offer and sell, from time to time, shares of its common stock having a maximum aggregate offering price of up to $75.0 million. As of September 30, 2022, no shares have been sold pursuant to the ATM program.

Organization and Description of the Business

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of the Business

Description of the Business

Tenaya Therapeutics, Inc. (Company) was incorporated in the state of Delaware in August 2016 and is headquartered in South San Francisco, California. The Company is a clinical-stage biotechnology company focused on discovering, developing and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing product candidates from three distinct but interrelated product platforms: gene therapy, cellular regeneration and precision medicine.

Liquidity

The Company has incurred net losses since inception and expects such losses to continue in the future as it conducts research and development activities. As of September 30, 2022, the Company had an accumulated deficit of $245.7 million. The Company incurred a net loss of $90.1 million and $46.6 million during the nine months ended September 30, 2022 and 2021, respectively. The Company had $149.5 million of cash, cash equivalents and investments in marketable securities as of September 30, 2022.

Management recognizes the need to raise additional capital to fully implement its business plan. The Company may seek to raise capital through equity financings, debt financings, license agreements, collaborative agreements or other sources of financing. Management believes that its existing cash, cash equivalents and investments in marketable securities as of September 30, 2022 will be sufficient to fund the Company’s operations for at least the next twelve months following the date these condensed financial statements are filed with the Securities and Exchange Commission (SEC).

In August 2022, the Company entered into a sales agreement with a sales agent to establish an at-the-market (ATM) offering program under the Securities Act. Pursuant to the sales agreement, the Company is permitted to offer and sell, from time to time, shares of its common stock having a maximum aggregate offering price of up to $75.0 million. As of September 30, 2022, no shares have been sold pursuant to the ATM program.